GlassScriptPhysician profile
Johnnie Watts
NPI 1679026785
$4,373.79
in general payments reported to CMS, 2019-2025
39 companies · $972 in 2025
The $972 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $883 · 2022: $948 · 2023: $662 · 2024: $908 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516 · Education: $26.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,515.92 |
| Education | $26.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $961.26 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Abbvie INC. | $482.24 | 2021-2025 | |
| Pfizer INC. | $270.56 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $230.70 | 2023-2025 | |
| Lilly USA, LLC | $203.53 | 2021-2024 | Amyvid, Emgality, Reyvow |
| Eisai INC. | $192.41 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $188.36 | 2021-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $175.91 | 2023 | Aptiom |
| Sunovion Pharmaceuticals INC. | $154.01 | 2021-2022 | |
| Lundbeck LLC | $145.88 | 2021-2025 | Vyepti, Abilify Asimtufii |
| Amgen INC. | $127.03 | 2021-2025 | Uplizna |
| Biogen, INC. | $124.21 | 2021-2025 | Leqembi |
| Janssen Pharmaceuticals, INC | $112.60 | 2021-2025 | Spravato, Invega Sustenna |
| Biohaven Pharmaceutical Holding Company LTD. | $99.80 | 2022 | |
| Neurelis, INC. | $97.55 | 2021-2025 | Valtoco |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnnie Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.